

FORM 7

**MONTHLY PROGRESS REPORT**

Name of Listed Issuer: Cannvas MedTech Inc. (the "Issuer" or "Cannvas").

Trading Symbol: MTEC

Number of Outstanding Listed Securities: 49,258,664

Date: May 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**See Item 2 below for a complete overview and discussion of the Issuer's activities for the month of April 2019.**

- 2. Provide a general overview and discussion of the activities of management.

**On April 9, 2019, the Issuer announced that Cannvas Cannabis Acquisitions Corp. ("Cannvas Cannabis"), a wholly-owned subsidiary with a focus on investment and acquisition in the expanding global cannabis sector, has been actively exploring opportunities with data-driven organizations across the United States to expand its dataset of cannabis consumer trends through strategic partnership and merger and acquisition opportunities, with a significant focus on the US \$2.5 billion California cannabis market.**

**With a population of nearly 40 million, approximately 10% of whom are legal medical cannabis users, California is considered to be among the largest recreational and medical cannabis markets in the world, alongside Canada. In the late 1990s, it was the first U.S. state to legalize medical cannabis and recreational cannabis sales became legal in January 2018. That year, California retail stores reportedly sold US \$2.5 billion of cannabis, compared to \$1.5 billion or lower in Colorado, Washington and Oregon. The golden state is projected to account for nearly \$25 billion of cannabis sales by 2026.**

**Reports indicate more than 30% of all cannabis sales in California in 2018 were vapes, demonstrating the growing trend of more sophisticated and discerning audiences looking to learn more about alternative and healthier methods of ingestion. Cannvas hopes to leverage its educational**

and data analytics properties and work with retailers to offer consumers more robust education around the potential health benefits of cannabis, increase incremental sales through accessible product knowledge and better target potential and active users through in-depth analytics.

While Cannabis is actively seeking growth opportunities with American cannabis data organizations, the Issuer is also exploring options with U.S. entities on the distribution and fulfillment sides of the cannabis industry. The United States will likely one day represent the world's largest cannabis market, with 65 percent of its population already residing in states where cannabis is either medically and/or recreationally legal. According to BDS Analytics, the U.S. legal cannabis market is projected to reach US \$20.9 billion by 2021.

On April 10, 2019, the Issuer announced that it has established a working partnership with US Cannabis Pharmaceutical Research and Development ("US Cannabis"), a resource for organizations seeking to normalize, legalize and develop medicinal cannabis. The deal positions Cannabis as an exclusive, leading provider of cannabis education and analytics to US Cannabis and its vast network of clients.

A key partnership for both organizations, Cannabis and US Cannabis will work together to deliver cannabis education to potential and active cannabis consumers through the Cannabis.Me digital learning resource. Cannabis will reinforce US Cannabis' goal of normalizing and developing medicinal and therapeutic cannabis through US Cannabis' vast partner network across the United States. Both companies believe educating the public about the investment, business and job opportunities around cannabis legalization will complement strengthened education on the plant's potential health benefits, and the Cannabis.Me platform is well-positioned to meet that challenge.

US Cannabis provides services to help an array of clients - from startups to seasoned investors, established operations to Native American tribes and government agencies. Cannabis will support these efforts through the licensing of educational software, the use of cannabis data and analytics to better understand key industry trends and drivers for the businesses with whom US Cannabis works closely, placement of Cannabis educational kiosks in existing US-based dispensaries and clinics, and other elements designed to elevate the level of learning Americans experience around cannabis. With more than a dozen states expected to pass new cannabis laws by 2025, according to New Frontier Data, the projected growth of the American cannabis market will provide many more opportunities for US Cannabis and Cannabis to work together as this partnership evolves.

On April 17, 2019, the Issuer announced that it has entered into a definitive partnership with California-based real estate brokerage Good Karma, an innovative two-year-old agency specializing in the California commercial market, to provide detailed analysis and insights into the California market through its Cannabis Data platform while also undertaking a contemporary rebrand of the company.

According to a recent Allen Matkins/UCLA Anderson Forecast California Commercial Real Estate Survey, overall retail sales in the U.S. have increased at a 5.3 percent annual rate while retail markets struggle in California due to the onset of e-commerce that has grown at a 10.7 percent rate. However, industrial real estate is trending upward in the golden state, dominated by warehousing and distribution centres. Among its plans, Cannabis hopes to work with Good Karma to identify key industrial sites to act as strategically-placed distribution hubs for cannabis retailers across the state.

Cannabis expects this partnership to facilitate conversations with California cannabis producers and retailers looking to leverage a growing and diversifying customer base increasingly turning to cannabis to curb unhealthy habits or replace/complement traditional pain medication. Through the use of demographic and firmographic data, Cannabis can identify desirable consumer behaviour traits in specific regions across the state, helping to drive decisions on where to open up shop and reach new and potential customers.

Good Karma was founded in Silicon Valley in 2016 by Len Sterling. A native of California and certified medical professional, Mr. Sterling has a reputation for prudent management from decades of experience in recruitment, sales and management.

On April 18, 2019, the Issuer announced that it has entered into a partnership with Empower Clinics Inc. (“Empower”) to launch a comprehensive education, data collection and analysis program starting with the installation of a network of standalone on-site Cannabis Kiosks in the Empower network of medical clinics.

The partnership installs Cannabis as the exclusive provider of cannabis education to Empower Clinics and its 120,000 patients in the U.S. Cannabis plans to place its Cannabis Kiosks throughout Empower’s network of clinics to provide accessible and unbiased cannabis education to its patients, integrating geo-targeting capabilities to ensure relevant contextual information across the country. Cannabis will also be a key data and analytics partner for Empower, providing meaningful insights on customer behaviours and industry trends and integrating mutually beneficial existing data partnerships.

Every month Empower hosts informational sessions about alternative treatment options and the potential health benefits with doctors and staff available to answer questions. Cannabis expects to play an active role in the review and implementation of new educational curriculum based on original content from Cannabis.Me.

The Company also plans to begin further pilot initiatives with Cannabis to provide content and educational links to Cannabis.me and Cannabis.health directly from the new Empower website [www.empowerclinics.com](http://www.empowerclinics.com) and through the Empower tele-medicine portal.

#### About Empower:

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

On April 24, 2019, the Issuer announced that it has joined the International Cannabis Alliance (“InterCannAlliance”), bringing advancements from existing legal cannabis markets to new and evolving legal cannabis markets around the globe, as its exclusive provider of cannabis education. The InterCannAlliance is an international project led by New Frontier Data, an independent, technology-driven analytics company specializing in the cannabis industry.

Cannvas will work with the InterCannAlliance to deliver physician-backed and evidence-based cannabis education powered by its digital cannabis learning resource Cannabis.Me. With a focus on audiences in new and evolving legal cannabis markets, InterCannAlliance will review all original content on Cannabis.Me and work with the Cannabis team to identify appropriate learning modules to adapt and make available to their community. The partnership also opens the door to opportunities for Cannabis to explore projects with New Frontier Data as part of its cannabis analytics platform Cannabis Data, as the two organizations share the same mission of elevating the discussion around the legal cannabis industry globally by providing unbiased vetted information and educating stakeholders to make informed decisions.

The International Cannabis Alliance was created in March of 2018 to bring advancements from existing legal cannabis markets to new and evolving legal cannabis markets around the globe. Its mission is to educate and inform future market and thought leaders interested in the cannabis

industry, fostering responsible, transparent and effective market practices learned across more mature North American cannabis sectors.

Uniting recognized leaders from industry segments considered to be critical building blocks for any cannabis market, InterCannAlliance seeks to simplify the complex and inconsistent regulatory environments being implemented across and within nations. The InterCannAlliance conducts one-day, invitation-only regional symposia to foster collaboration among governments, non-governmental organizations and commercial enterprises to educate stakeholders about opportunities, risks, and challenges in these markets.

#### About InterCannAlliance:

The International Cannabis Alliance (InterCannAlliance) was created in March of 2018 to bring advancements from existing legal cannabis markets to new and evolving legal cannabis markets around the globe. As established and emerging markets look to cannabis to reinvigorate their economies, healthcare and a range of industries, InterCannAlliance unites recognized leaders from industry segments considered to be critical building blocks for any cannabis market. The organization seeks to simplify the complex and inconsistent regulatory environments being implemented across and within nations and to help emerging markets capitalize on lessons learned elsewhere. The InterCannAlliance conducts invitation-only quarterly regional symposia to facilitate collaboration among governments, non-government organizations and large commercial enterprises to expedite access to and assessment of opportunities while accelerating growth. For more information, visit [www.intercannalliance.com](http://www.intercannalliance.com).

On April 25, 2019, the Issuer announced that it has signed an agreement with Le Qlub, a premier Quebec-based exotic car rental company, to be its exclusive provider of cannabis education with the luxury automobile club as the first member of the Cannabis Drive Responsible Program. The agreement also supports revenue-sharing between the two organizations with Le Qlub offering exclusive discounts and promotions to Cannabis users.

Cannvas will provide printed educational material to be placed prominently in each vehicle in Le Qlub's fleet, including mirror hangers, window decals and glovebox flyers. Each piece will have information on safe cannabis consumption as it relates to driving, using material created for the Cannabis.Me digital cannabis education resource by the platform's independent Medical, Educational and Cannabis Sciences Advisory Boards.

The agreement also sets in place a lead-generating aspect wherein Le Qlub will offer exclusive discounts and promotions to Cannabis users, encouraging residents of and visitors to Quebec to complement their trip with the enjoyment of a reasonably-priced rental of a luxury automobile of their choice.

The agreement brings Le Qlub on board as the inaugural member of the Cannabis Drive Responsible Program, an initiative aimed at increasing awareness of the risks associated with driving under the influence of cannabis. According to a Statistics Canada report in the second quarter of 2018, "one in seven cannabis users reported driving at least once within two hours of using cannabis in the past three months, and one in 20 Canadians reported being a passenger in a vehicle driven by someone who had consumed cannabis in the previous two hours."

#### About Le Qlub

Le Qlub™ is a premier exotic car rental company for individuals in search of an exotic car rental in Montreal. Le Qlub™ provides a pristine luxury experience for new and experienced clientele. For more information please visit [LeQlub.ca](http://LeQlub.ca).

On April 30, 2019, the Issuer announced that it has signed a revenue sharing agreement with Medical Marijuana Patient Relief Inc. ("MM Patient Relief"), a private locally-owned producer based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains. Cannabis

and MM Patient Relief are jointly deploying technologies to increase value-added services offered between company platforms while driving customer integration.

Canvas expects to leverage its data analysis capabilities and work with MM Patient Relief to generate revenue through tracking the number of Canvas.Me users who choose MM Patient Relief as their primary cannabis provider, and can track purchases made throughout the lifetime of a patient.

Established in 2014, Medical Marijuana Patient Relief Inc. is currently in the final stages of review and approval under Health Canada's MMPR/ACMPR (Access to Cannabis for Medical Purposes Regulations).

#### **About Medical Marijuana Patient Relief**

Established in 2014, Medical Marijuana Patient Relief Inc. (MM Patient Relief) is a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains for pain, arthritis, and cancer. Using advanced cultivation methods that maximize production and have increased the number of yearly crop cycles from four to six, MM Patient Relief is in the final stage of Health Canada MMPR / ACMPR (Access to Cannabis for Medical Purposes Regulation) approval and finalizing construction of its state-of-the-art stand-alone facility. For more information: [www.mmpatientrelief.com](http://www.mmpatientrelief.com)

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**See Item 2 above. Good Karma, US Cannabis, Empower Clinics, Le Qlub and MM Patient Relief are not Related Parties of the Issuer.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**N/A.**

8. Describe the acquisition of new customers or loss of customers.

**N/A.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**N/A.**

14. Provide details of any securities issued and options or warrants granted.

**None.**

Provide details of any loans to or by Related Persons.

**N/A.**

15. Provide details of any changes in directors, officers or committee members.

**None.**

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Changes in commodity prices, in particular metal prices, and changes in the share performance of other junior mineral exploration companies may affect the Issuer's ability to raise financing.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2019

Shawn Moniz  
Name of Director or Senior Officer

"Shawn Moniz"  
Signature

CEO & Director  
Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer	For Month End	Date of Report YY/MM/D
<b>Canvas MedTech Inc.</b>	<b>April 2019</b>	<b>19/04/06</b>
Issuer Address <b>201-213 Sterling Road</b>		
City/Province/Postal Code <b>Toronto, ON M6R 2B2</b>	Issuer Fax No. <b>N/A</b>	Issuer Telephone No. <b>800.489.0116</b>
Contact Name <b>Shawn Moniz</b>	Contact Position <b>CEO &amp; Director</b>	Contact Telephone No. <b>800.489.0116</b>
Contact Email Address <a href="mailto:info@canvasmedtech.com">info@canvasmedtech.com</a>	Web Site Address <a href="http://www.canvasmedtech.com">www.canvasmedtech.com</a>	